Portal de Periódicos da CAPES

Elective high-frequency oscillatory versus conventional ventilation in preterm infants: a systematic review and meta-analysis of individual patients' data

2010; Elsevier BV; Volume: 375; Issue: 9731 Linguagem: Inglês

10.1016/s0140-6736(10)60278-4

1474-547X

Filip Cools, Lisa Askie, Martin Offringa, Jeanette Asselin, Sandra Calvert, Sherry E. Courtney, Carlo Dani, David J. Durand, Dale R. Gerstmann, David J Henderson‐Smart, Neil Marlow, Janet L. Peacock, J. Jane Pillow, Roger F. Soll, Ulrich Thomé, Patrick Truffert, Michael Schreiber, Patrick Van Reempts, Valentina Vendettuoli, Giovanni Vento,

Neuroscience of respiration and sleep

Background Population and study design heterogeneity has confounded previous meta-analyses, leading to uncertainty about effectiveness and safety of elective high-frequency oscillatory ventilation (HFOV) in preterm infants. We assessed effectiveness of elective HFOV versus conventional ventilation in this group. Methods We did a systematic review and meta-analysis of individual patients' data from 3229 participants in ten randomised controlled trials, with the primary outcomes of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age, death or severe adverse neurological event, or any of these outcomes. Findings For infants ventilated with HFOV, the relative risk of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age was 0·95 (95% CI 0·88–1·03), of death or severe adverse neurological event 1·00 (0·88–1·13), or any of these outcomes 0·98 (0·91–1·05). No subgroup of infants (eg, gestational age, birthweight for gestation, initial lung disease severity, or exposure to antenatal corticosteroids) benefited more or less from HFOV. Ventilator type or ventilation strategy did not change the overall treatment effect. Interpretation HFOV seems equally effective to conventional ventilation in preterm infants. Our results do not support selection of preterm infants for HFOV on the basis of gestational age, birthweight for gestation, initial lung disease severity, or exposure to antenatal corticosteroids. Funding Nestlé Belgium, Belgian Red Cross, and Dräger International.